Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 25, 2025 08:19 ET | Source: Biomerica, Inc.

Biomerica’s inFoods® IBS Product Featured in Biotherapeutics Quarterly, a Henry Schein Publication, Highlighting a New Precision Approach for Treating IBS

Publication details large multicenter clinical trial demonstrating significant reductions in IBS symptoms through inFoods IBS guided dietary therapy IRVINE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE)...
November 12, 2025 08:00 ET | Source: NeurAxis, Inc.

NeurAxis Announces New Medical Policy Coverage in Michigan, Adding 566,000 Covered Lives

CARMEL, Ind., Nov. 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic...
November 12, 2025 05:00 ET | Source: Yaqrit

First patient dosed in a proof-of-concept study of Yaqrit’s advanced microbiome therapeutic YAQ001 in patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Disease

Yaqrit progresses novel treatment into pilot study for primary sclerosing cholangitis and IBD. Results expected H2 2026
November 11, 2025 07:00 ET | Source: NeurAxis, Inc.

NeurAxis Reports Strong Third Quarter 2025 Financial Results Driven by a 22% Growth in Revenues

CARMEL, Ind., Nov. 11, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for...
November 04, 2025 08:30 ET | Source: NeurAxis, Inc.

NeurAxis to Host Third Quarter 2025 Results and Business Update Call on Tuesday, November 11, 2025

CARMEL, Ind., Nov. 04, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...
October 16, 2025 08:19 ET | Source: Biomerica, Inc.

Henry Schein and Biomerica Enter into Marketing Services Agreement for Biomerica’s inFoods® IBS Test in the U.S.

- Expands Marketing of Non-Drug IBS Symptom Management Test Through One of the Nation’s Most Trusted Health Care Distributors- Relationship Marks a Key Milestone in Biomerica’s Commercialization...
September 18, 2025 08:00 ET | Source: NeurAxis, Inc.

NeurAxis to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025

CARMEL, Ind., Sept. 18, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies...
September 09, 2025 08:08 ET | Source: Biomerica, Inc.

Biomerica Launches AI-Backed inFoods® IBS Trigger Food Navigator to Support Personalized IBS Therapy and Improve Patient Outcomes

New AI-enabled digital tool empowers patients to confidently manage IBS symptoms and avoid the trigger foods identified by inFoods® IBS testingIBS affects an estimated 40 million adults in the U.S....
August 12, 2025 07:00 ET | Source: NeurAxis, Inc.

NeurAxis Reports Strong Second Quarter 2025 Financial Results Driven by a 46% Growth in Revenues

CARMEL, Ind., Aug. 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for...
August 05, 2025 08:30 ET | Source: NeurAxis, Inc.

NeurAxis to Host Second Quarter 2025 Results and Business Update Call on Tuesday, August 12, 2025

CARMEL, Ind., Aug. 05, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...